TRANSDERMAL ESTRADIOL THERAPY FOR PROSTATE CANCER REDUCES THROMBOPHILIC ACTIVATION AND PROTECTS AGAINST THROMBOEMBOLISM

Citation data:

The Journal of Urology, ISSN: 0022-5347, Vol: 174, Issue: 2, Page: 527-533

Publication Year:
2005
Usage 25
Abstract Views 25
Captures 9
Exports-Saves 9
Mentions 2
References 2
Social Media 1
Shares, Likes & Comments 1
Citations 33
Citation Indexes 33
Repository URL:
https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/333; https://works.bepress.com/elnasir_lalani/90
DOI:
10.1097/01.ju.0000165567.99142.1f
Author(s):
Ockrim, Jeremy L.; Lalani, El-Nasir; Kakkar, Ajay K.; Abel, Paul D.
Publisher(s):
Elsevier BV
Tags:
Medicine; Prostatic neoplasms; Estradiol; Cutaneous administration; Thrombosis; Male Urogenital Diseases; Oncology; Pathology
article description
Oral estrogens were an effective treatment for prostate cancer but were abandoned because of an increased risk of cardiovascular toxicity and particularly thromboembolism. We have recently shown that transdermal estradiol produces an effective tumor response and negligible cardiovascular toxicity. Here we report the influence of transdermal estradiol therapy on the coagulation profile of men with advanced prostate cancer.